Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis

Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. Alemtuzumab demonstrated high efficacy in several clinical studies. The risk of relapse and sustained accumulation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarnera, Cristina, Bramanti, Placido, Mazzon, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522829/
https://www.ncbi.nlm.nih.gov/pubmed/28761351
http://dx.doi.org/10.2147/TCRM.S134398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522829/
https://www.ncbi.nlm.nih.gov/pubmed/28761351
http://dx.doi.org/10.2147/TCRM.S134398

Ejemplares similares